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Abstract  
Studies of antipsychotic medication, which are increasingly prescribed for a broad range 
of problems and circumstances, rarely ask the people who take them to describe their 
experiences with the drugs. In this study 650 people, from 29 countries, responded, in an 
online survey, to ‘Overall in my life antipsychotic medications have been ……….?’ and 
‘Is there anything else you would like to say, or emphasise, about your experiences with 
anti-psychotic drugs?’ 14.3%  of participants were categorised as reporting purely 
positive experiences, 27.9% had mixed experiences, and 57.7% reported only negative 
ones. Negative experiences were positively correlated with age. Thematic analysis 
identified 749 negative, 180 positive, and 53 mixed statements. The two positive themes 
were ‘symptom reduction’ (14) and ‘sleep’ (14), with the majority (153) unspecified. The 
four negative themes (besides ‘unspecified’ - 191) were: ‘adverse effects’ (316), 
‘interactions with prescriber’ (169), ‘withdrawal/difficult to get off them’ (62) and 
‘ineffective’ (11). The adverse effects included: weight gain, emotional numbing, 
cognitive dysfunction, sedation, akathisia, withdrawal effects, effects on relationships, 
and suicidality. ‘Interactions with prescribers’ included lack of information, support, or 
discussion of alternatives. The only mixed theme was ‘short-term good, long-term bad’ 
(28). Open questions can add to findings from methodologies focussed on symptom 
reduction. Clinicians should pay more attention to the need for respectful and 
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collaborative patient-prescriber relationships. At the point of prescription this must 
include providing the full range of information about antipsychotics, including potential 
benefits and harms, the difficulty in withdrawing, and information on alternatives 
treatments such as psychological therapies. 
 




Current guidelines1,2 recommend antipsychotic medication for people diagnosed with 
‘schizophrenia’ and other diagnoses indicative of psychosis. Antipsychotic drugs are also 
increasingly used for other mental health problems and with adolescents, older people and 
prisoners.  Recent studies and reviews, however, suggest that claims about their efficacy 
may have been overstated.3-8 A recent meta-analysis of 167 RCTs found that 23% in the 
drug group and 14% on placebos had a ‘good response’.9 Adverse effects can be severe. 
They include tardive dyskinesia, cardiovascular effects (e.g.cardiac arrythmia, 
lengthening of Q-T interval, sudden cardiac death), metabolic effects (e.g. glucose 
intolerance, diabetes, high cholesterol levels, obesity), sexual dysfunction, sedation, 
dizziness, akathisia, dry mouth, reduced brain volume, and shortened life span.3,10-14  
Thus far, surveys or interviews about the first-hand experience of people taking these 
drugs have not played a significant role in evaluating these drugs. Some of these 
qualitative studies confirm a plethora of commonly experienced and disruptive biological 
adverse effects (e.g. neurological, metabolic, cardiovascular), but have also identified a 
range of negative effects and functional impairments in the less well researched 
psychological and interpersonal domains.15-20  A few studies have focussed on the 
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difficulties of withdrawing.21-24  Others have addressed the prescribing and decision-
making processes.25-27  A recent study of 20 antipsychotic users26 found opinions divided 
between ‘willing acceptance’ to taking antipsycotics, ‘resigned acceptance’ and ‘non-
acceptance’, but ‘They commonly experienced their prescribing psychiatrist as not 
sufficiently acknowledging the negative impacts of medication on life quality and 
physical health concerns.’ Even 69 British people who mostly found antipsychotics 
helpful, did not feel involved in treatment decisions and had not been warned about side 
effects or offered alternative treatments.28  
The largest survey to date, of 832 antipsychotic users from 30 countries, found that 
64% reported ten or more adverse effects; including sedation (92%) and suicidality 
(58%). Equal proportions found the drugs ‘helpful’ (41%) and ‘unhelpful’ (43%). The 
current paper reports the qualitative data, from the same survey, to reveal what it is that 
people find helpful and unhelpful about antipsychotics.29  
 
Methods  
The study was approved, in Melbourne, by Swinburne University of Technology's Human 
Research Ethics Committee. 
 
Instrument  
The Experiences of Antidepressant and Antipsychotic Medication Survey,29,30 an online 
questionnaire, has quantitative and open questions about: prescribing experience, positive 
and negative effects of medications, causal beliefs, alternative treatments, and 
withdrawal. This paper reports responses to two open questions: ‘Overall in my life 
antipsychotic medications have been _____?’ and, at the end of the survey, ‘Is there 
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Of the 2,346 people who responded 668 were recruited by an Australian research 
company, and 1,678 people via advertisements on social media and snowball sampling.30 
963 met the following criteria: ‘I have been taking or have previously taken antipsychotic 
medication continuously for at least one month’; ‘I am aged 18 or older’; and ‘I am not 
currently compulsorily detained in a psychiatric hospital’.29 Fifty-one matched the 
Internet Protocol address of another response, indicating the same device was used; 23 of 
these were excluded because of identical demographics or similar responses. Of the 
remaining 938, 27 responded to ‘What is the name of your current or most recent 
antipsychotic medication?’ with something other than antipsychotics. Of the remaining 
911, 261 did not respond to either question, leaving 650 to be included in the analysis.  
 
Data Analysis  
Responses to the two questions were combined for each participant. A Likert scale, from 
1 - ‘extremely positive’ to 7 - ‘extremely negative’ (Table 1), provided an Overall 
Antipsychotic Rating (OAR) score.  Reliability was assessed by one of the researchers 
independently scoring 20 random items, blind to the scores of the main scorer. Inter-rater 
reliability was 95% (19/20). This translates to a kappa, which allows for expected 
agreement by chance, of 0.94. Kappa scores above 0.75 are considered ‘excellent’.31 The 
relationship of OAR scores with age and treatment duration were analysed with spearman 
rank correlation coefficients (rho), and with gender using a two-tailed t-test.  
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Thematic analysis32 was used to identify themes. Units of analysis (participants’ 
written answers, or parts thereof) were first classified as positive, negative or mixed; and 
then into themes, and sub-themes, by one of the researchers. The other researcher 
independently assigned 44 units of analysis to the 22 sub themes generated by the main 
coder, blind to their original coding (one each of the 22 subthemes and an additional 
random 22). Inter-rater reliability was 86.4% (38/44), which is a kappa of 0.857. The six 
discrepancies included overlapping subthemes. For example, ‘withdrawal’ and ‘difficult 
to get off them’ were initially separate categories, but it was agreed they were too similar 
and were combined into one category.  
 




The majority of the sample (71.6%) were women. Ages ranged from 18 to 76, with an 
average of 43.0 (sd 13.07). Participants were from 29 countries, but the majority (72.2%) 
were from the USA (25.1%), Australia (24.5%) or the UK (22.6%). Other countries 
contributing more than 1% were: New Zealand (4.5%), Canada (3.8%), Netherlands 
(3.1%), Denmark (2.5%), Ireland (2.5%), Germany (2.2%), Norway (1.8%), South Africa 
(1.4%) and Switzerland 1.2%. The following contributed from one to five participants: 
Austria, Belgium, Croatia, Estonia, Finland, France, Greece, India, Israel, Italy, 
Lithuania, Poland, Portugal, Romania, Spain, Sweden, Ukraine. The most frequently 
reported ethnicities (self-definition) were ‘white’/‘Caucasian’ 319 (49.1%), ‘Australian’ 
73 (11.2%) and ‘European’ 36 (6.0%). A quarter (24.6%) had taken antipsychotics for 1 
to 12 months, 18.1% for one to three years, and 57.2% for more than three years.  
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Of the 650 participants, 579 provided their ‘primary diagnosis’. DSM-V groupings 
cited by five or more participants were represented as follows:’ Schizophrenia Spectrum 
and Other Psychotic Disorders’ - 200 (34.5%); ‘Bipolar and Related Disorders’ - 140 
(21.5%); ‘Depressive Disorders’ - 137 (21.1%); ‘Personality Disorders’ - 42 (7.3%); 
‘Trauma and Stressor-Related Disorders’ - 19 (3.3%); ‘Obsessive-Compulsive and 
Related Disorders’ - 8 (1.4%); ‘Anxiety Disorders’ - 8 (1.4%); ‘Dissociative Disorders’ 
- 6 (1.0%); and ‘Neurodevelopmental Disorder’s - 5 (0.9%). Secondary diagnoses 
included 49 in the schizophrenia spectrum, bringing the total (primary of secondary) for 
that grouping to 249 (43.0%). 
In the survey’s quantitative section29 roughly equal numbers of the 650 in the current 
sample reported that the drugs were ‘helpful’ (40.1%) and ‘unhelpful’ (44.5). More 
found that the drugs had ‘reduced the problems for which they were prescribed’ (55.4%) 
than thought they had been made ‘worse’ (27.6%). More reported that their ‘Quality of 
Life’ had been made worse (56.0%) than thought it had been ‘improved’ (34.9%).  
 
Rating Scores 
Table 1 shows that two thirds (66.9%) of the participants were categorised as more 
negative than positive, with 34.9% being ‘extremely negative’. Nearly a quarter of 
participants’ responses (22.1%) were categorised as more positive than negative, with 
5.7% ‘extremely positive’. Mixed responses comprised over a quarter of participants’ 
responses (27.9%), with 10.9% categorised as equally balanced.  
The mean score on the OAR scale (1-7) was 2.83 (sd 1.93), well to the negative side of 
the midpoint of 4. OAR was not related to gender or duration of treatment. Older age was 
related to lower, more negative, scores (rho = .13, p = .001). The 249 respondents with a 
primary or secondary diagnosis in the schizophrenic spectrum had a significantly more 
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negative mean OAR score (2.53) than those without such a diagnosis (2.99) (t = 2.90, df 
= 577, p = .004). Nevertheless, the majority of both groups were categorised as more 
negative than positive (schizophrenia - 72.7%; other - 63.3%). 
 
Thematic Analysis 
Most of the 982 individual statements (units of analysis) were clearly either positive (180; 
18.3%) or negative (749; 76.3%). There were 53 instances (5.4%) where the positive and 
negative components of a mixed statement could not be separated into smaller units of 
assessment without losing meaning, most commonly statements about short versus long 
term experiences. Positive quotes were categorised into three themes (see Table 2 for 
examples from each of the three themes). Mixed quotes were categorised into two themes 
(Table 3). Negative quotes were categorised into five themes, two of which were further 
divided into subthemes (Tables 4 and 5).  
 
Tables 2 - 5 About Here 
 
Discussion 
This is the largest survey directly addressing people’s experiences with antipsychotics. In 
this sample, of 650 people from 29 countries, open questions led to negative experiences 
far outweighing positive ones, with many participants reporting mixed accounts. This 
suggests that studies focussing on symptom reduction, including RCTs, may be missing 
the broader impact of drugs on people’s lives.  
 
Positive Experiences 
Nearly a quarter of participants’ responses (22.1%) were categorised as more positive 
than negative on the OAR scale (scale points 5-7). 5.7% were scored as ‘extremely 
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positive’, with several people characterising the drugs as life-changing or even life-
saving. In the thematic analysis 18.3% of the units of analysis were positive with a further 
5.4% mixed. These findings are similar to the meta-analysis of 167 double-blind 
randomised controlled trials which found that an average of 23% had a ‘good’ response.9 
In the current study relatively few people who experienced the drugs positively were able 
to articulate specifically why or how. Only 14 people said the drugs reduced psychotic 
symptoms. Of the 180 units coded as positive, 153 (85.0%) were ‘unspecified’ but this 
was the case for only 25.5% of the negative units (191/749).   
 
Negative Experiences 
The broad range, and high frequencies of the adverse effects reported, such as emotional 
numbing/sedation, weight gain, and cognitive dysfunction, are broadly consistent with 
previous studies, both qualitative15-18,33 and quantitative.3,4,11 Further research and clinical 
attention are urgently needed to address the incidence and severity of withdrawal effects 
and suicidality. In the current sample these were reported by 65% and 58% respectively 
when asked directly in another section of the survey.29 The recent schizophrenia 
guidelines published by the German Association for Psychiatry, Psychotherapy and 
Psychosomatics34 is, to our knowledge, the first national guidelines to properly address 
withdrawal from antipsychotics. 
Another area in need of greater focus is the long-term adverse effects, which some 
participants reported continued even after coming off the drugs.  
Another major finding emanating from use of open questions rather than closed 
questions on topics chosen by researchers, is that the negative opinions were not just 
based on the adverse effects of the drugs prescribed, but also, in large numbers, on 
dissatisfaction with interactions with the prescriber, or with mental health services in 
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general. Despite neither of the questions asking about the topic, 169 comments were 
about lack of information or support. Failure to fully inform people of adverse effects 
breaches the fundamental ethical principle of informed consent. Yet, in the quantitative 
section of the survey only 30.2% replied ‘yes’ to ‘Did the doctor inform you of any 
possible side effects?’, identical to the larger sample29 (which included those who did not 
respond to the two questions analysed here. This is comparable to the extent to which 
people are told about the adverse effects of antidepressants.30,35-37 Other qualitative studies 
of users of antipsychotics have highlighted the import of relationships with prescribers.25-28,38  
The 21 participants who reported they were not given an alternative to antipsychotic 
medication align with a recent study that found practitioners were often reluctant to 
consider reduction or to propose alternative approaches to antipsychotics.39 This is 
inconsistent with the recommendation that decision making should be shared.2   
The finding that older age is correlated with more negative OAR scores is matched by 
quantitative data from the same survey,29 and by other studies finding particularly high 
rates of adverse effects in older people.40-42 This is of particular concern given the increasing 
inappropriate, ‘off-label’ use of antipsychotics with older people, especially those in care.42,43 
The findings from this study regarding short term benefit/long-term negatives, and 
functional impairment, are consistent with previous studies demonstrating greater long 
term functional impairment in those staying on antipsychotics for several years.3,12,17,44-47  
Reviews show that alternatives to antipsychotic medications may have equally good, or 
better, outcomes.3, 47-49  Examples of moves towards alternatives are the ‘Open Dialogue’ 
approach,50 the Hearing Voices Network,51 and the government-mandated creation of 
drug-free treatment options in Norway.52 
Many of the problems that need addressing here were captured by a 40 year old 
woman in the UK  who answered the first question with ‘Necessary evil’ and added, in 
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response to the second question,  ‘Should have been told about side effects, shouldn't 
have been brushed off when I raised concerns about side effects, shouldn't have been left 
to take them long term, should have been able to discuss other options’. 
 
Limitations 
A limitation of this study is that it uses a convenience sample, not a randomly selected one. It 
is possible that people who were dissatisfied with their antipsychotics were more likely to 
participate. More than half, however, had reported that the drugs had to some extent 
reduced the problems for which they had been prescribed, a figure far higher than most 
drug trials report.9 Even if the sample were biased, towards either those with positive or 
negative experiences, the study still provides important insights into what the largest 
sample to date find helpful and unhelpful about taking antipsychotic drugs. 
The fact that it was an online survey may mean that the economically disadvantaged 
may be underrepresented because of lack of internet access. People from ‘developing’ 
countries and ethnic minorities were certainly underrepresented. 
Another limitation is that the data was self-reported. Some of the adverse effects may 
not have been related to the antipsychotics. It is also possible that some of the positive 
outcomes may have resulted from life changes, spontaneous remission, or placebo effects. 
 
Conclusions 
Asking open-ended questions about first-hand experiences allows deeper insight than 
asking participants to respond to specific questions predetermined by the researchers. The 
650 people who gave their time to share their experiences, positive and painful, seem to 
be telling us that the important things for clinicians (and researchers) to pay attention to 
include: establishing a collaborative, respectful relationship with potential users of 
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antipsychotics, which requires the provision of full information about all possible adverse 
effects, including suicidality and withdrawal effects, and about alternative treatment 
pathways; and responding respectfully and therapeutically when patients voice the sorts 
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Criteria Examples  
1 Extremely negative: 
Superlatives (‘very’ or 
‘extremely’) OR strong or 
extremely negative descriptor 
‘torturous’, ‘disastrous’, 
‘poison’ ‘extreme pain’ 
227 (34.9%) 
2 Negative: 





3 Mixed, mostly negative:  
More negative than positive 
issues identified 
‘felt disconnected, gained 
weight and felt like an 
emotional zombie, but they did 
help me sleep’ 
60 (9.2%) 
4 Equally balanced:  
Equal number of positive and 
negative issues OR one 
extreme that balances out 
several minor issues 
‘beneficial but problematic’, 
‘mixed blessing’ 
‘helpful short-term, unhelpful 
long-term’ 
‘a saviour and a curse both’ 
71 (10.9%) 
5 Mixed, mostly positive:  
More positive than negative 
issues identified 
‘reduced hallucinations, 
delusions and re-connected me 




All positive but without 
extremes  
‘helpful’, ‘effective’ 56 (8.6%) 
7 Extremely positive: 
Superlatives (‘very’ or 
‘extremely’) OR strong or 
extremely positive descriptor 








Table 2: Positive Experiences (n= 180) 
 





It’s helpful. I don’t want to stop taking my medication 
 
Having the medication makes it possible to thrive instead of just 
surviving on a day to day basis  
 
It was the right choice of treatment. I benefitted greatly from using it 
 
I consider being prescribed antipsychotic medication to have allowed 
me to start living a life and have a future that I had never even 
imagined as a teenager as I didn't think I would be alive 
 
I don't know how I would survive without them   
 
I cannot over-estimate their helpfulness. My life is hell without them 
32 M India 
 
48 M Netherlands 
 
33 F USA  
 
 
37 F South Africa  
 




31 F USA 
 




If forgotten to take sleep is impossible   
 
They are not ‘antipsychotic’ they just helped me sleep   
35 F UK 
  
53 M Canada 
 
SYMPTOM REDUCTION (n=14) 
 
They stopped the voices, and bought me back to reality 
 
They have taken away delusions and paranoia   
 
I had an alternative to suicide / self-harm and stopping my distressing 
thoughts and extreme emotions  
39 F Ireland  
 
40 F Ireland  
 





Table 3: Mixed Experiences (n = 53) 
 
UNSPECIFIED MIXED EXPEREINCES (n=25) 
age, gender, 
couintry 
Necessary, but not without heavy price 
 
Beneficial but problematic 
 
Is a necessary evil 
33 F USA 
 
45 F UK 
 
31 M UK 
 
SHORT TERM GOOD, LONG TERM BAD (n=28) 
 
Useful in the short term, a curse in long term use   
 
Maybe helpful for a short time, but likely not worth it in the end they 
clouded my perceptions and sense of self very badly 
 
Good short (very short term) but hurting my feeling competent 
person if insisted to use life-long.  
 
There are times they are necessary in certain doses and temporarily, 
but it is not the solution to the problem long term  
 
Helpful until they were harmful. At this point it’s hard to know 
what’s caused by the drug or helped by it!  
49 M NZ 
 
34 M ? 
 
 
61 F Lithuania 
 
 
39 F Spain 
 
 
24 F USA 
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Table 4. Negative Themes and Subthemes I: Adverse Effects  
 
  








The side effects were bad enough that I considered stopping the 
treatment 
 
Awful side effects I never had before being put forced to take 
injections depot  
 
I don't feel like the benefits of the anti-psychotic have been 
worth the negative side effects for me   
 
Virtually every anti-psychotic I tried gave me very serious side 
effects 
23 F UK 
 
 
66 F UK 
 
 
28 F NZ 
 
 
31 F USA 
2 Physical 





My body is still scarred with stretch marks from the 
uncontrollable weight gain 
 
The fight against weight gain is a nightmare 
  
I think they made me gain like 10kg and that bummed me out 
as a teens/20s girl  
 
I put on 27 kgs and developed diabetes   
24 M USA 
 
 
73 F UK 
 
26 F UK  
 
 





 I refuse to call these medications anti-psychotics. They are 
major tranquilisers  
 
Severe sedation made it impossible to continue    
40 M Austr.  
 
 




Very damaging to my mental and physical health  
  
It contributed to the deterioration in my physical health 
59 F USA  
 




 I developed severe akathisia within a week of the first dose of 
Depixol. It lasted over 3 months and ended in a hospital 
admission  
 
The inner restlessness was probably one of the worst side 
effects I have ever experienced. Developed muscle spasms, 
jerking limbs, twitching, inner agitation, restless legs and could 
no longer function   
 
Created an at times unbearable internal restlessness that drove 
me to suicidal thoughts  















Due to the rather large doses I have long-term TD and seizures   
 
The big movements are ugly, the small ones make you look 
stupid, your mouth is never comfortable again, there are always 
sores from teeth clamping down, and tongue has no place to 
35 M Austr.  
 
55 F UK 
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rest and feels it does not belong in your mouth. I wish they had 
killed me instead 
3 Psychological 





 I was very emotionally numb when on antipsychotics  
 
If the point of antipsychotics is to make you an emotional and 
spiritual zombie, they succeeded  
 
They dumb me down & numb me up, I have no happiness or 
joy  
 
They made me feel less than human, dead inside   
 
Terrible side effects. Zombified and unable to collect thoughts  
 
It also shut down the good/happy things and the lively energy. 
… just emptied the whole world from meaning and shut me 
down completely.   
20 F USA 
 
27 F USA 
 
  
44 M Ireland 
 
39 F UK 
 
58 F UK 
 







They took away the one thing I had previously been able to rely 
on; my mind, and rendered it useless   
 
I was frightened about my loss of mental acuity   
 
These are difficult drugs to take. Having cotton wool for a brain 
was not easy  
51 F NZ 
 
 
63 F USA  
 
27 F UK 
 





 20mg of olanzapine gave me the worst hallucinations I have 
ever experienced   
 
They caused psychosis, something I hadn't experienced before 
 
It did not make the voices go away it increased the amount of 
voices and how often I heard them   
48 F NZ 
 
 
70 F Norway 
 
50 F Austr.  
 
4 Long Term 
(n=31) 
 
It has now been over 4 years and I am still suffering severe side 
effects 
 
 I have long term physical issues as a result of their use, 
including tremors and an auto-immune response associated 
with taking long term pharmaceuticals         
 
2+ years after stopping still have sleep issues as withdrawal 
symptoms 
 
I believe my health has been permanently damaged and my life 
shortened by unnecessary psychiatric drugging  
45 M NZ 
 
 




72 F Austr. 
 
 





 Antipsychotics were life shattering. Imagine not being able to 
connect with partners anymore   
 
 I lost 10 years of my life. I withdrew from my sons, my 
siblings, and my friends  
28 F Canada  
 
 




Loss of concentration meant I couldn’t keep up friendships etc.   
 
I could not relate to my partner and 4 children   
 
74 F Austr. 
 




Worst experience of my life. I had such severe akathisia (a side 
effect from antipsychotics) I felt like killing myself  
 
My first and only suicide attempt was because of the 
restlessness of akathisia. No one would believe how much pain 
I was in   
 
When I am not on psychiatric medication I am not suicidal. 
 I want professionals and medication users to acknowledge 
suicidality can happen  
 
The flattening of my emotional, sexual, and social state was 
unbearable. This lack of pleasure in my life drove me to 
suicidal ideation.  No attempt was made, but it got to a plan  
 
Antipsychotics made me suicidal, and I tried to kill myself 
when under CTO. I've never been suicidal when not on 
antipsychotics   
41 F UK 
 
 



















Table 5. Negative Themes and Subthemes II: Unspecified, Interactions with Prescriber, 
Withdrawal and Ineffective  
  
UNSPECIFIED NEGATIVE EXPERIENCES (n = 191) 
age, gender, 
country 
 Taking them was a very frightening experience. I would 
never want to repeat it 
 
A disaster. Anti-psychotics took away the best years of my 
life 
 
Basically makes life unliveable, pointless and increases 
suffering 
 
These medications are disabling. They are dehumanising  
 
Antipsychotics are poisons 
43 F USA 
 
 
42 F USA 
 
 
23 M Estonia 
 
 
40 M Austr. 
 
48 M Canada 
  
INTERACTIONS WITH PRESCRIBER (n = 169) 
 
 
1 Lack of Support 
(n=64) 
 
My psychiatrist would not support any sort of medication 
reduction so I did it myself by going cold turkey - not 
something I would recommend! 
 
My suffering continues and I have NO SUPPORT from the 
medical profession 
 
I am now being refused support because I am deemed as 
"non compliant"  
 
Why did no one listen to me?  
 
… through the hell of withdrawal with zero support from the 
medical community 
 
lack of professional and personal support 




22 M NZ 
 
 
26 F UK  
 
 
46 F UK 
 
 
34 F NZ 
 
58 F Norway 
2 Lack of 
Informed Consent 
(n = 56) 
 
If I had known about the risks of this medications I would have 
never have taken them  
 
I don't think the potential side effects are explained well 
enough or the impact they have on your life taken seriously 
enough  
 
I think, given the significant side effects, it is important to 
clearly communicate to the patient the real risks involved, the 
purpose of it, what the plan is for its use (short or long term). 
This didn’t happen for me   
 
30 M UK 
 
 










I was not warned about permanent/semi-permanent effects of 
antipsychotics which I got 
 
I was told NOTHING about them   
 
The info from the doctors is very slanted and does not fully 
warn you of long-term effects   
 
I think I would have gained better results earlier, with more 
information from the beginning   
 
22 F Ukraine 
 
 
59 F UK 
 
50 F NZ 
 
 
46 F Norway 




being presented with medications as the only possibility to 
feel relief from overwhelming distress turns the decision into: 
‘feel this afraid and miserable forever or take these 
medications   
 
Why wasn’t I told about alternative mental health 
help/methods?   
 
Other avenues should definitely be explored before resorting 
to prescribing anti-psychotics. I literally just met this doctor 
for the first time, had a half an hour long conversation and 
BOOM  
 
 I wish there was alternative treatment available like 
psychotherapy when i needed help 










25 F UK 
 
 
28 M India 





 (n = 17) 
If I had known the seriousness of withdrawing from my 
medication, I would have not relapsed 
 
They never talk about withdrawal or secondary withdrawals   
 
Most doctors do not have a clue. They turn their backs on 
suffering patients, denying the existence of withdrawal 
damage  
35 F UK  
 
 
41 F USA 
 




I had never expected I would be prescribed antipsychotics 
given my symptoms and diagnosis are entirely consistent with 
anxiety. I have zero psychotic symptoms   
 
‘Akathisia was misdiagnosed as ‘agitated depression’ and 
‘converted from depression to bipolar’, requiring MORE 
meds   





46 M UK 
  
WITHDRAWAL/DIFFICULT TO GET OFF (n = 62) 
 
 
  I wish I never started. Now i am slowly quitting, but 
withdrawel is terrible  
 
 It was not worth it and it took a full darned year to finish 
withdrawals and even begin to feel normal 
 38 F Nether. 
 
 




I suffered hallucinations, and headaches during withdrawal 
even from stopping a low dosage  
 
The withdrawls process has runied 4 years of my life so far 
and counting  
 
The withdrawal process was horrible and caused very 
distressing physical, mental and emotional changes   
 
The withdrawal process was almost worse than the illness 
itself  
 
Withdrawal from the anti-psychotic was torturous and took a 
very long time. I would never choose to take them again, ever 
 
Withdrawal symptoms were always blamed on relapse of my 
"disease"  
 
 32 F UK  
 
 
 52 M USA 
 
 
 35 F USA 
 
 
 41 F USA 
 
 
 34 F Austr. 
 
 
34 F USA 
  
INEFFECTIVE (n = 11) 
 
 
 They do not work   58 F UK 
 
 
 
 
 
 
 
 
 
 
 
 
